Lifetime costs of COPD in the Netherlands

T. L. Feenstra, M. P. M. H. Rutten-van Molken, M. M. L. van Genugten (Bilthoven, Rotterdam, The Netherlands)

Source: Annual Congress 2002 - Prevalence and costs of COPD
Session: Prevalence and costs of COPD
Session type: Thematic Poster Session
Number: 829
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
T. L. Feenstra, M. P. M. H. Rutten-van Molken, M. M. L. van Genugten (Bilthoven, Rotterdam, The Netherlands). Lifetime costs of COPD in the Netherlands. Eur Respir J 2002; 20: Suppl. 38, 829

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Projections of future costs of asthma and COPD in the Netherlands
Source: Eur Respir J 2005; 26: Suppl. 49, 383s
Year: 2005

Health care utilization and costs of asthma and COPD in the Netherlands
Source: Eur Respir J 2005; 26: Suppl. 49, 383s
Year: 2005

Costs of COPD and asthma in Sweden
Source: Eur Respir J 2004; 24: Suppl. 48, 701s
Year: 2004

Societal costs of severe asthma in Sweden
Source: International Congress 2018 – Epidemiology of asthma and allergy: prevalence, incidence and risk factors
Year: 2018

The costs of adult asthma in Denmark
Source: Annual Congress 2011 - Comorbidities and impact on society of asthma and COPD
Year: 2011


Epidemiology and costs of COPD
Source: Eur Respir J 2006; 28: 1290
Year: 2006


Costs of asthma care in Belgium
Source: Eur Respir J 2001; 18: Suppl. 33, 441s
Year: 2001

The drug costs associated with COPD prescription medicine in Denmark
Source: Annual Congress 2012 - Looking at the cost effectiveness of asthma and COPD treatment by novel drugs and improved management
Year: 2012


Asthma: prevalence and cost of illness
Source: Eur Respir J 2005; 25: 47-53
Year: 2005



Alcohol consumption and hospitalisations due to COPD
Source: Eur Respir J 2001; 18: Suppl. 33, 274s
Year: 2001

Trends in COPD-related hospitalisations in Sweden
Source: Eur Respir J 2003; 22: Suppl. 45, 217s
Year: 2003

Risk factors for self-reported hospitalizations among stable outpatients with COPD
Source: Annual Congress 2013 –The best posters in chronic care
Year: 2013


Predictive value of annual costs on 3-year mortality in COPD
Source: International Congress 2015 – Patient health gains related to the economic effectiveness of disease management programmes
Year: 2015


Prescription rates for various classes of COPD & asthma medication in Turkey
Source: Eur Respir J 2001; 18: Suppl. 33, 425s
Year: 2001

Active tobacco smoking and costs of COPD exacerbations in secondary medical care in Poland
Source: Eur Respir J 2007; 30: Suppl. 51, 194s
Year: 2007

Severity distribution of physician-diagnosed COPD in the Netherlands
Source: Eur Respir J 2003; 22: Suppl. 45, 67s
Year: 2003

Social distancing and admissions for severe exacerbations of COPD – a nationwide study
Source: Virtual Congress 2021 – COPD burden, epidemiology and management
Year: 2021

Trends in the lifetime risk of COPD exacerbation requiring hospitalisation
Source: Eur Respir J 2013; 42: 964-971
Year: 2013



Corerelation of COPD exacerbation with comorbidities, Lung function and mortality within a single-practice primary-care cohort in the UK
Source: International Congress 2019 – Multimorbidity in airway diseases and appropriate inhaled corticosteroid use in COPD
Year: 2019